Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66.
Bed Bath & Beyond, America’s Car-Mart And Some Other Big Stocks Moving Lower On Thursday
Bed Bath & Beyond Inc. (NASDAQ: BBBY) fell 23.3% to $17.71 following a Form 144 filing by RC Ventures, which suggested the firm proposed to sell 7.78 million common shares and certain call options. Additionally, Wedbush downgraded the stock to Underperform.
SVB Leerink Maintains Market Perform on bluebird bio, Raises Price Target to $10
SVB Leerink analyst Mani Foroohar maintains bluebird bio (NASDAQ:BLUE) with a Market Perform and raises the price target from $8 to $10.
Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat…
Bluebird’s Gene Therapy Scores US Approval For Genetic Blood Disorder, Probably The Most Expensive
The FDA has approved Bluebird bio Inc’s (NASDAQ:BLUE) Zynteglo (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed for…
Bluebird Bio Announces U.S. Commercial Infrastructure To Enable Patient Access To ZYNTEGLO
Price of ZYNTEGLO reflects potentially curative clinical benefit through achievement of durable transfusion independence and normal or near normal total hemoglobin levels
Innovative outcomes-based contract offering
Bluebird Bio PR Announces FDA Approval Of ZYNTEGLO
ZYNTEGLO offers potentially curative benefit across ages and genotypes, through the achievement of durable transfusion independence and normal or near normal total hemoglobin levels
Management team to host conference
‘Bluebird wins U.S. approval for a gene therapy to treat patients with a rare blood disorder’ -STAT
https://www.statnews.com/2022/08/17/bluebird-wins-fda-approval-for-gene-therapy-for-beta-thalassemia/?utm_content=bufferba14a&utm_medium=social&utm_source=twitter&utm_campaign=twitter_organic